Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

A Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein (EBOV GP) Nanoparticle Vaccine with Matrix-M™ Adjuvant in Healthy Adults.

Fries L, Cho I, Krähling V, Fehling SK, Strecker T, Becker S, Hooper JW, Kwilas SA, Agrawal S, Wen J, Lewis M, Fix A, Thomas N, Flyer D, Smith G, Glenn G.

J Infect Dis. 2019 Oct 11. pii: jiz518. doi: 10.1093/infdis/jiz518. [Epub ahead of print]

PMID:
31603201
2.

Progress on the Prevention and Treatment of Hantavirus Disease.

Brocato RL, Hooper JW.

Viruses. 2019 Jul 4;11(7). pii: E610. doi: 10.3390/v11070610. Review.

3.

Three asymptomatic animal infection models of hemorrhagic fever with renal syndrome caused by hantaviruses.

Perley CC, Brocato RL, Kwilas SA, Daye S, Moreau A, Nichols DK, Wetzel KS, Shamblin J, Hooper JW.

PLoS One. 2019 May 10;14(5):e0216700. doi: 10.1371/journal.pone.0216700. eCollection 2019.

4.

Human Polyclonal Antibodies Produced from Transchromosomal Bovine Provides Prophylactic and Therapeutic Protections Against Zika Virus Infection in STAT2 KO Syrian Hamsters.

Siddharthan V, Miao J, Van Wettere AJ, Li R, Wu H, Sullivan E, Jiao J, Hooper JW, Safronetz D, Morrey JD, Julander JG, Wang Z.

Viruses. 2019 Jan 22;11(2). pii: E92. doi: 10.3390/v11020092.

5.

Innate immune responses elicited by Sin Nombre virus or type I IFN agonists protect hamsters from lethal Andes virus infections.

Brocato RL, Wahl V, Hammerbeck CD, Josleyn MD, McElroy AK, Smith JM, Hooper JW.

J Gen Virol. 2018 Aug 1. doi: 10.1099/jgv.0.001131. [Epub ahead of print]

PMID:
30067171
6.

Intranasal monkeypox marmoset model: Prophylactic antibody treatment provides benefit against severe monkeypox virus disease.

Mucker EM, Wollen-Roberts SE, Kimmel A, Shamblin J, Sampey D, Hooper JW.

PLoS Negl Trop Dis. 2018 Jun 21;12(6):e0006581. doi: 10.1371/journal.pntd.0006581. eCollection 2018 Jun.

7.

Correction: A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.

Callendret B, Vellinga J, Wunderlich K, Rodriguez A, Steigerwald R, Dirmeier U, Cheminay C, Volkmann A, Brasel T, Carrion R, Giavedoni LD, Patterson JL, Mire CE, Geisbert TW, Hooper JW, Weijtens M, Hartkoorn-Pasma J, Custers J, Grazia Pau M, Schuitemaker H, Zahn R.

PLoS One. 2018 Apr 24;13(4):e0196546. doi: 10.1371/journal.pone.0196546. eCollection 2018.

8.

A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.

Callendret B, Vellinga J, Wunderlich K, Rodriguez A, Steigerwald R, Dirmeier U, Cheminay C, Volkmann A, Brasel T, Carrion R, Giavedoni LD, Patterson JL, Mire CE, Geisbert TW, Hooper JW, Weijtens M, Hartkoorn-Pasma J, Custers J, Grazia Pau M, Schuitemaker H, Zahn R.

PLoS One. 2018 Feb 20;13(2):e0192312. doi: 10.1371/journal.pone.0192312. eCollection 2018. Erratum in: PLoS One. 2018 Apr 24;13(4):e0196546.

9.

A lethal disease model for New World hantaviruses using immunosuppressed Syrian hamsters.

Vergote V, Laenen L, Vanmechelen B, Van Ranst M, Verbeken E, Hooper JW, Maes P.

PLoS Negl Trop Dis. 2017 Oct 27;11(10):e0006042. doi: 10.1371/journal.pntd.0006042. eCollection 2017 Oct.

10.

Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial.

Agnandji ST, Fernandes JF, Bache EB, Obiang Mba RM, Brosnahan JS, Kabwende L, Pitzinger P, Staarink P, Massinga-Loembe M, Krähling V, Biedenkopf N, Fehling SK, Strecker T, Clark DJ, Staines HM, Hooper JW, Silvera P, Moorthy V, Kieny MP, Adegnika AA, Grobusch MP, Becker S, Ramharter M, Mordmüller B, Lell B; VEBCON Consortium, Krishna S, Kremsner PG.

PLoS Med. 2017 Oct 6;14(10):e1002402. doi: 10.1371/journal.pmed.1002402. eCollection 2017 Oct.

11.

Gastrointestinal Tract As Entry Route for Hantavirus Infection.

Witkowski PT, Perley CC, Brocato RL, Hooper JW, Jürgensen C, Schulzke JD, Krüger DH, Bücker R.

Front Microbiol. 2017 Sep 8;8:1721. doi: 10.3389/fmicb.2017.01721. eCollection 2017.

12.

Human polyclonal antibodies produced in transchromosomal cattle prevent lethal Zika virus infection and testicular atrophy in mice.

Stein DR, Golden JW, Griffin BD, Warner BM, Ranadheera C, Scharikow L, Sloan A, Frost KL, Kobasa D, Booth SA, Josleyn M, Ballantyne J, Sullivan E, Jiao JA, Wu H, Wang Z, Hooper JW, Safronetz D.

Antiviral Res. 2017 Oct;146:164-173. doi: 10.1016/j.antiviral.2017.09.005. Epub 2017 Sep 8.

PMID:
28893603
13.

An attenuated Machupo virus with a disrupted L-segment intergenic region protects guinea pigs against lethal Guanarito virus infection.

Golden JW, Beitzel B, Ladner JT, Mucker EM, Kwilas SA, Palacios G, Hooper JW.

Sci Rep. 2017 Jul 5;7(1):4679. doi: 10.1038/s41598-017-04889-x.

14.

Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.

ElSherif MS, Brown C, MacKinnon-Cameron D, Li L, Racine T, Alimonti J, Rudge TL, Sabourin C, Silvera P, Hooper JW, Kwilas SA, Kilgore N, Badorrek C, Ramsey WJ, Heppner DG, Kemp T, Monath TP, Nowak T, McNeil SA, Langley JM, Halperin SA; Canadian Immunization Research Network.

CMAJ. 2017 Jun 19;189(24):E819-E827. doi: 10.1503/cmaj.170074.

15.

Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle.

Dye JM, Wu H, Hooper JW, Khurana S, Kuehne AI, Coyle EM, Ortiz RA, Fuentes S, Herbert AS, Golding H, Bakken RA, Brannan JM, Kwilas SA, Sullivan EJ, Luke TC, Smith G, Glenn G, Li W, Ye L, Yang C, Compans RW, Tripp RA, Jiao JA.

Sci Rep. 2016 Apr 25;6:24897. doi: 10.1038/srep24897.

16.

Depletion of Alveolar Macrophages Does Not Prevent Hantavirus Disease Pathogenesis in Golden Syrian Hamsters.

Hammerbeck CD, Brocato RL, Bell TM, Schellhase CW, Mraz SR, Queen LA, Hooper JW.

J Virol. 2016 Jun 24;90(14):6200-6215. doi: 10.1128/JVI.00304-16. Print 2016 Jul 15.

17.

Glycoprotein-Specific Antibodies Produced by DNA Vaccination Protect Guinea Pigs from Lethal Argentine and Venezuelan Hemorrhagic Fever.

Golden JW, Maes P, Kwilas SA, Ballantyne J, Hooper JW.

J Virol. 2016 Jan 20;90(7):3515-29. doi: 10.1128/JVI.02969-15.

18.

Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.

Bounds CE, Kwilas SA, Kuehne AI, Brannan JM, Bakken RR, Dye JM, Hooper JW, Dupuy LC, Ellefsen B, Hannaman D, Wu H, Jiao JA, Sullivan EJ, Schmaljohn CS.

PLoS One. 2015 Sep 30;10(9):e0137786. doi: 10.1371/journal.pone.0137786. eCollection 2015.

19.

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.

Huttner A, Dayer JA, Yerly S, Combescure C, Auderset F, Desmeules J, Eickmann M, Finckh A, Goncalves AR, Hooper JW, Kaya G, Krähling V, Kwilas S, Lemaître B, Matthey A, Silvera P, Becker S, Fast PE, Moorthy V, Kieny MP, Kaiser L, Siegrist CA; VSV-Ebola Consortium.

Lancet Infect Dis. 2015 Oct;15(10):1156-1166. doi: 10.1016/S1473-3099(15)00154-1. Epub 2015 Aug 4.

20.

Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses.

Willet M, Kurup D, Papaneri A, Wirblich C, Hooper JW, Kwilas SA, Keshwara R, Hudacek A, Beilfuss S, Rudolph G, Pommerening E, Vos A, Neubert A, Jahrling P, Blaney JE, Johnson RF, Schnell MJ.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S414-24. doi: 10.1093/infdis/jiv251. Epub 2015 Jun 10.

21.

Antiviral Biologic Produced in DNA Vaccine/Goose Platform Protects Hamsters Against Hantavirus Pulmonary Syndrome When Administered Post-exposure.

Haese N, Brocato RL, Henderson T, Nilles ML, Kwilas SA, Josleyn MD, Hammerbeck CD, Schiltz J, Royals M, Ballantyne J, Hooper JW, Bradley DS.

PLoS Negl Trop Dis. 2015 Jun 5;9(6):e0003803. doi: 10.1371/journal.pntd.0003803. eCollection 2015.

22.

Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges.

Grant-Klein RJ, Altamura LA, Badger CV, Bounds CE, Van Deusen NM, Kwilas SA, Vu HA, Warfield KL, Hooper JW, Hannaman D, Dupuy LC, Schmaljohn CS.

Hum Vaccin Immunother. 2015;11(8):1991-2004. doi: 10.1080/21645515.2015.1039757.

23.

A Recombinant Vesicular Stomatitis Virus Ebola Vaccine.

Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, Muñoz P, Moon JE, Ruck RC, Bennett JW, Twomey PS, Gutiérrez RL, Remich SA, Hack HR, Wisniewski ML, Josleyn MD, Kwilas SA, Van Deusen N, Mbaya OT, Zhou Y, Stanley DA, Jing W, Smith KS, Shi M, Ledgerwood JE, Graham BS, Sullivan NJ, Jagodzinski LL, Peel SA, Alimonti JB, Hooper JW, Silvera PM, Martin BK, Monath TP, Ramsey WJ, Link CJ, Lane HC, Michael NL, Davey RT Jr, Thomas SJ; rVSVΔG-ZEBOV-GP Study Group.

N Engl J Med. 2017 Jan 26;376(4):330-341. doi: 10.1056/NEJMoa1414216. Epub 2015 Apr 1.

24.

Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein.

Martins K, Carra JH, Cooper CL, Kwilas SA, Robinson CG, Shurtleff AC, Schokman RD, Kuehl KA, Wells JB, Steffens JT, van Tongeren SA, Hooper JW, Bavari S.

Viral Immunol. 2015 Feb;28(1):62-70. doi: 10.1089/vim.2014.0071.

PMID:
25514232
25.

DNA vaccine-derived human IgG produced in transchromosomal bovines protect in lethal models of hantavirus pulmonary syndrome.

Hooper JW, Brocato RL, Kwilas SA, Hammerbeck CD, Josleyn MD, Royals M, Ballantyne J, Wu H, Jiao JA, Matsushita H, Sullivan EJ.

Sci Transl Med. 2014 Nov 26;6(264):264ra162. doi: 10.1126/scitranslmed.3010082.

26.

A highly specific monoclonal antibody against monkeypox virus detects the heparin binding domain of A27.

Hughes LJ, Goldstein J, Pohl J, Hooper JW, Lee Pitts R, Townsend MB, Bagarozzi D, Damon IK, Karem KL.

Virology. 2014 Sep;464-465:264-273. doi: 10.1016/j.virol.2014.06.039. Epub 2014 Aug 9.

27.
28.

A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for haemorrhagic fever with renal syndrome delivered by intramuscular electroporation.

Hooper JW, Moon JE, Paolino KM, Newcomer R, McLain DE, Josleyn M, Hannaman D, Schmaljohn C.

Clin Microbiol Infect. 2014 May;20 Suppl 5:110-7. doi: 10.1111/1469-0691.12553. Epub 2014 Mar 7.

29.

DNA vaccines for HFRS: laboratory and clinical studies.

Schmaljohn CS, Spik KW, Hooper JW.

Virus Res. 2014 Jul 17;187:91-6. doi: 10.1016/j.virusres.2013.12.020. Epub 2013 Dec 24.

PMID:
24370868
30.

Ribavirin protects Syrian hamsters against lethal hantavirus pulmonary syndrome--after intranasal exposure to Andes virus.

Ogg M, Jonsson CB, Camp JV, Hooper JW.

Viruses. 2013 Nov 8;5(11):2704-20. doi: 10.3390/v5112704.

31.

A lethal disease model for hantavirus pulmonary syndrome in immunosuppressed Syrian hamsters infected with Sin Nombre virus.

Brocato RL, Hammerbeck CD, Bell TM, Wells JB, Queen LA, Hooper JW.

J Virol. 2014 Jan;88(2):811-9. doi: 10.1128/JVI.02906-13. Epub 2013 Nov 6.

32.

A novel Sin Nombre virus DNA vaccine and its inclusion in a candidate pan-hantavirus vaccine against hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS).

Hooper JW, Josleyn M, Ballantyne J, Brocato R.

Vaccine. 2013 Sep 13;31(40):4314-21. doi: 10.1016/j.vaccine.2013.07.025. Epub 2013 Jul 24.

33.

Construction and nonclinical testing of a Puumala virus synthetic M gene-based DNA vaccine.

Brocato RL, Josleyn MJ, Wahl-Jensen V, Schmaljohn CS, Hooper JW.

Clin Vaccine Immunol. 2013 Feb;20(2):218-26. doi: 10.1128/CVI.00546-12. Epub 2012 Dec 12.

34.

Side-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primates.

Golden JW, Josleyn M, Mucker EM, Hung CF, Loudon PT, Wu TC, Hooper JW.

PLoS One. 2012;7(7):e42353. doi: 10.1371/journal.pone.0042353. Epub 2012 Jul 31.

35.

The Syrian hamster model of hantavirus pulmonary syndrome.

Safronetz D, Ebihara H, Feldmann H, Hooper JW.

Antiviral Res. 2012 Sep;95(3):282-92. doi: 10.1016/j.antiviral.2012.06.002. Epub 2012 Jun 15. Review.

36.

DNA vaccine-generated duck polyclonal antibodies as a postexposure prophylactic to prevent hantavirus pulmonary syndrome (HPS).

Brocato R, Josleyn M, Ballantyne J, Vial P, Hooper JW.

PLoS One. 2012;7(4):e35996. doi: 10.1371/journal.pone.0035996. Epub 2012 Apr 27.

37.

A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome.

Boudreau EF, Josleyn M, Ullman D, Fisher D, Dalrymple L, Sellers-Myers K, Loudon P, Rusnak J, Rivard R, Schmaljohn C, Hooper JW.

Vaccine. 2012 Mar 2;30(11):1951-8. doi: 10.1016/j.vaccine.2012.01.024. Epub 2012 Jan 14.

PMID:
22248821
38.

Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.

Golden JW, Zaitseva M, Kapnick S, Fisher RW, Mikolajczyk MG, Ballantyne J, Golding H, Hooper JW.

Virol J. 2011 Sep 20;8:441. doi: 10.1186/1743-422X-8-441.

39.

The strategic use of novel smallpox vaccines in the post-eradication world.

Golden JW, Hooper JW.

Expert Rev Vaccines. 2011 Jul;10(7):1021-35. doi: 10.1586/erv.11.46. Review.

PMID:
21806397
40.

T cells are not required for pathogenesis in the Syrian hamster model of hantavirus pulmonary syndrome.

Hammerbeck CD, Hooper JW.

J Virol. 2011 Oct;85(19):9929-44. doi: 10.1128/JVI.05356-11. Epub 2011 Jul 20. Erratum in: J Virol. 2012 Apr;86(7):4043.

41.

Development and application of a flow cytometric potency assay for DNA vaccines.

Badger CV, Richardson JD, Dasilva RL, Richards MJ, Josleyn MD, Dupuy LC, Hooper JW, Schmaljohn CS.

Vaccine. 2011 Sep 9;29(39):6728-35. doi: 10.1016/j.vaccine.2010.12.053. Epub 2011 Jan 8.

PMID:
21219978
42.

Evaluating the orthopoxvirus type I interferon-binding molecule as a vaccine target in the vaccinia virus intranasal murine challenge model.

Golden JW, Hooper JW.

Clin Vaccine Immunol. 2010 Nov;17(11):1656-65. doi: 10.1128/CVI.00235-10. Epub 2010 Sep 15.

43.

Study of Andes virus entry and neutralization using a pseudovirion system.

Ray N, Whidby J, Stewart S, Hooper JW, Bertolotti-Ciarlet A.

J Virol Methods. 2010 Feb;163(2):416-23. doi: 10.1016/j.jviromet.2009.11.004. Epub 2009 Nov 10.

PMID:
19903496
44.

Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates.

Hooper JW, Ferro AM, Golden JW, Silvera P, Dudek J, Alterson K, Custer M, Rivers B, Morris J, Owens G, Smith JF, Kamrud KI.

Vaccine. 2009 Dec 11;28(2):494-511. doi: 10.1016/j.vaccine.2009.09.133. Epub 2009 Oct 13.

45.

Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies.

Golden JW, Josleyn MD, Hooper JW.

Vaccine. 2008 Jun 25;26(27-28):3507-15. doi: 10.1016/j.vaccine.2008.04.017. Epub 2008 Apr 28.

PMID:
18485547
46.

Mixing of M segment DNA vaccines to Hantaan virus and Puumala virus reduces their immunogenicity in hamsters.

Spik KW, Badger C, Mathiessen I, Tjelle T, Hooper JW, Schmaljohn C.

Vaccine. 2008 Sep 19;26(40):5177-81. doi: 10.1016/j.vaccine.2008.03.097. Epub 2008 Apr 25.

PMID:
18482782
47.

Heterogeneity in the A33 protein impacts the cross-protective efficacy of a candidate smallpox DNA vaccine.

Golden JW, Hooper JW.

Virology. 2008 Jul 20;377(1):19-29. doi: 10.1016/j.virol.2008.04.003. Epub 2008 May 14.

48.

Immune serum produced by DNA vaccination protects hamsters against lethal respiratory challenge with Andes virus.

Hooper JW, Ferro AM, Wahl-Jensen V.

J Virol. 2008 Feb;82(3):1332-8. Epub 2007 Nov 21.

49.

Genome-wide association study for Crohn's disease in the Quebec Founder Population identifies multiple validated disease loci.

Raelson JV, Little RD, Ruether A, Fournier H, Paquin B, Van Eerdewegh P, Bradley WE, Croteau P, Nguyen-Huu Q, Segal J, Debrus S, Allard R, Rosenstiel P, Franke A, Jacobs G, Nikolaus S, Vidal JM, Szego P, Laplante N, Clark HF, Paulussen RJ, Hooper JW, Keith TP, Belouchi A, Schreiber S.

Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14747-52. Epub 2007 Sep 5.

50.

Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein.

Su HP, Golden JW, Gittis AG, Hooper JW, Garboczi DN.

Virology. 2007 Nov 25;368(2):331-41. Epub 2007 Aug 3.

Supplemental Content

Loading ...
Support Center